Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for MediciNova, Inc. (MNOV : NSDQ)
 
 • Company Description   
MEDICINOVA, INC. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanesepharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and twopreclinical-stage compounds for the treatment of thrombotic disorders. MediciNova will seek to monetize its other product candidates at key value inflection points.

Number of Employees: 11

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.40 Daily Weekly Monthly
20 Day Moving Average: 32,338 shares
Shares Outstanding: 49.04 (millions)
Market Capitalization: $117.70 (millions)
Beta: 1.16
52 Week High: $5.09
52 Week Low: $2.09
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -19.73% -9.59%
12 Week 2.13% 12.28%
Year To Date -10.45% 9.42%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
4275 EXECUTIVE SQUARE SUITE 300
-
LA JOLLA,CA 92037
USA
ph: 858-373-1500
fax: 858-404-0048
info@medicinova.com http://www.medicinova.com
 
 • General Corporate Information   
Officers
Yuichi Iwaki - Director; President and Chief Executive Officer
Jeff Himawan - Chairman of the Board of Directors
Douglas Paulin - Chief Financial Officer
Carolyn Beaver - Director
Kazuko Matsuda - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 58468P206
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 49.04
Most Recent Split Date: (:1)
Beta: 1.16
Market Capitalization: $117.70 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.27 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.46
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -100.00%
vs. Previous Quarter: -100.00%
ROE
03/31/22 - -15.70
12/31/21 - -11.52
09/30/21 - -13.01
ROA
03/31/22 - -14.94
12/31/21 - -10.99
09/30/21 - -12.37
Current Ratio
03/31/22 - 23.13
12/31/21 - 25.42
09/30/21 - 18.13
Quick Ratio
03/31/22 - 23.13
12/31/21 - 25.42
09/30/21 - 18.12
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -34,623.72
12/31/21 - -250.92
09/30/21 - -273.35
Book Value
03/31/22 - 1.64
12/31/21 - 1.71
09/30/21 - 1.77
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©